Target intelligence / Profile preview

Influenza A virus hemagglutinin H1 (H1 HA)

Target
H1 HA
Molecular classification
Viral surface glycoprotein, Class I fusion protein, Lectin, Type I transmembrane protein
01

Overview

Influenza A virus hemagglutinin H1 (H1 HA) is a critical surface glycoprotein found on the envelope of H1-subtype influenza A viruses, including the strains responsible for the 1918 and 2009 pandemics [UniProt: P03452]. It functions as a class I viral fusion protein, mediating the initial attachment of the virus to host cell sialic acid receptors and the subsequent fusion of the viral envelope with the endosomal membrane. The protein is synthesized as a precursor, HA0, which must be proteolytically cleaved into HA1 and HA2 subunits to trigger infectivity [NCBI: NBK11444]. HA1 contains the highly variable globular head and receptor-binding site, while HA2 contains the more conserved fusion peptide and stem region.

As the primary target for neutralizing antibodies, H1 HA is the central component of most seasonal and pandemic influenza vaccines [CDC: Influenza Vaccines]. However, the protein's rapid evolution through antigenic drift allows the virus to evade host immunity, requiring frequent vaccine updates [WHO: Influenza]. Therapeutic interventions targeting H1 include small-molecule fusion inhibitors like umifenovir and broadly neutralizing monoclonal antibodies that target the conserved stem region to prevent the conformational changes necessary for membrane fusion [PubChem: CID 131411; ].

Other names
Hemagglutinin H1H1HAHA1Influenza A H1N1 hemagglutininViral surface glycoprotein H1
02

Mechanism of action

Inhibition of viral-host membrane fusion, blocking of receptor binding sites to prevent viral attachment, and prevention of HA0 precursor cleavage [PubChem: CID 131411; ].

03

Biological functions

Viral attachmentMembrane fusionReceptor bindingViral entryEndocytosis
04

Disease associations

Influenza ARespiratory tract infectionPandemic influenzaViral pneumonia
05

Safety considerations

Antigenic driftAntigenic shiftStrain-specific resistanceVaccine mismatchEgg-based mutation during manufacturing
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Hemagglutination inhibition (HAI) titerMicroneutralization (MN) titerAnti-HA antibody concentration

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Influenza A virus hemagglutinin H1 (H1 HA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A virus hemagglutinin H1 (H1 HA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call